Novo Nordisk wins FDA approval for once-weekly insulin

What: Novo Nordisk has secured FDA approval for a once-weekly insulin, marking a significant development in diabetes treatment.
Why: The approval is expected to boost Novo Nordisk's market share in the insulin market, which is highly competitive.
Signal: This approval signals a shift towards more convenient and user-friendly insulin options, potentially improving patient adherence.
Target: The company is likely targeting a significant portion of the **$40 billion** global insulin market with this new product.
Risk: However, the approval also poses a risk to competitors, such as Eli Lilly and Sanofi, which may see their market share decline.